October 31, 2013 / 9:37 AM / in 4 years

U.S. authorities quiz AstraZeneca over Brilinta clinical trial

LONDON, Oct 31 (Reuters) - AstraZeneca is being investigated by U.S. authorities over a major clinical trial that was used to win marketing approval for its new heart drug Brilinta.

The British drugmaker said on Thursday it had received a civil investigative demand from the U.S. Department of Justice seeking documents and information regarding the so-called PLATO study.

AstraZeneca, which highlighted the investigation in its quarterly results statement, gave no further details but said it intended to cooperate with the inquiry.

Brilinta is a key new product for the company, although its progress to date has been slow, with sales in the third quarter edging up to $75 million from $65 million in the three months to end-June.

A key challenge for Brilinta is the fact that U.S. doctors tend to use high-dose aspirin for cardiovascular patients and clinical trials suggest AstraZeneca’s new drug does not work as well in this setting.

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below